$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

Safety Of CD47 Asset A Major Attraction?

 
• By Ian Haydock
  
CD47
CD47, The Subject Of Major New I-Mab/AbbVie Alliance • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer